Small molecules to treat cancer, Gene therapies for hereditary diseases, soil bacteria for better harvest yields and strategies to protect bees – the latest edition of research provides an exclusive insight into the current research projects at Bayer. All of the articles in the magazine are also available from the online edition of research, along with animations, videos and image galleries.
LEVERKUSEN, 06-Nov-2017 — /EuropaWire/ — “Targeting the causes of cancer” is the title of the cover story in the recently published 31st edition of “research”, the Bayer Scientific Magazine. The report looks at new approaches in cancer research using small molecules to interact with cancer specific signaling pathways to destroy tumor cell selectively. Biomarkers play a decisive role here. After all, every tumor is different, just as every person is an individual. Research and development is therefore focused on individualized therapies for each patient, the so called precision medicine. State-of-the-art research methods permit scientists detailed insights into the biology of tumor cells, giving them access to previously inconceivable therapeutic opportunities.
Hereditary diseases such as hemophilia A, which is caused by a thoroughly researched gene defect, will likewise be able to be treated with novel methods better than ever before in the future. Researchers plan to use their findings to develop a gene therapy to treat the disease, or possibly even cure it. The objective of gene therapies is to insert a healthy version of the defective gene into the patient’s genome. You can read about how this method could help patients in the special report on “Treating hemophilia with gene surgery”.
On a two-page graphic spread, research explains how plant researchers are developing microbial seed treatments to increase harvest yields. Their work is based on the fact that plants and soil bacteria have co-existed in a symbiosis from which both benefit for millions of years. Bayer scientists have enhanced this relationship so that the bacteria stimulate crop growth better than ever before.
Just how important it is to get the right experts together at the right time and to create conditions in which new ideas can flourish is illustrated by the numerous collaborations that Bayer maintains with partners all over the world. For example, Bayer researchers are collaborating with scientists from the renowned Broad Institute in Boston and the German Cancer Research Center in Heidelberg to jointly conduct research into cardiovascular diseases and cancer, with the objective of developing new therapeutic options. The latest discoveries resulting from these collaborations are outlined in the current edition of research.
The thoroughly researched articles in the magazine explain how life science research can enhance the lives of humans, animals and plants. Explanatory graphics, fascinating photo sequences and videos shot in the laboratory or the field, and interviews with renowned scientists round off the topics while presenting new information and technologies in an attractive format.
research, the Bayer Scientific Magazine, can be ordered free of charge online at www.bayer.de/de/research.aspx, by phone at +49 214/30-57546, by fax at +49 214/30-57547 or by e-mail at firstname.lastname@example.org.
The online edition of research: bringing science to life
research, the Bayer Scientific Magazine, is also available online. Visit www.research.bayer.com to immerse yourself in the world of research at Bayer. Fascinating animated sequences, videos and numerous photo galleries make science accessible and comprehensible.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 99,600 people and had sales of EUR 34.9 billion. Capital expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 4.4 billion. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
SOURCE: Bayer AG
Dr. Katharina Jansen
Science / Research
Phone: +49 214 30-33243
Fax: +49 214 30-58923